Many factors have been demonstrated to mediate potential mechanisms of the response or resistance to antibodies targeting PD-1/PD-L1 axis, such as PD-L1 expression levels of tumor cells, TIL, tumor mutation burden, etc. [30, 31]. The gene discussed is PDCD1; the disease is neoplasm.